| abstract |
The present disclosure relates to, among other things, compounds that bind to the C5d domain of complement component C5 (e.g., human complement component C5) and compounds that comprises all or part of human C5d. In some embodiments, the compounds described herein inhibit the interaction between C5b and C6 and, thus, inhibit formation of the terminal complement complex (e.g., the assembly and/or activity of the C5b-9 TCC). Also featured are methods for producing and/or screening for such compounds as methods therapeutic applications in which the compounds can be used. |